5-(2-Aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 792-804

  Ruchelman, Alexander L ^a   Houghton, Peter J ^b   Zhou, Nai ^c   Liu, Angela ^c   Liu, Leroy F ^c,d   LaVoie, Edmond J ^a,d  

^a RUTGERS UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5H 8,9 DIMETHOXY 5 (2 N,N DIMETHYLAMINOETHYL) 2,3 METHYLENEDIOXYBENZO[C,H] [1,6]NAPHTHYRIDIN 6 ONE; ARC 111; NAPHTHYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; METHYLATION; MOLECULAR RECOGNITION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, SCID; NAPHTHYRIDINES; P-GLYCOPROTEIN; PIPERAZINES; PIPERIDINES; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 13444291906     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049447z     Document Type: Article

References (61)

1. Li, T.-K.; Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2002, 41, 53-77.
2. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1985, 54, 665-697.
3. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375.
4. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
5. Hsiang, Y. H.; Lihou, M.; Liu, L. Arrest or replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49, 5077-5082.
6. Desai, S. D.; Li, T.-K.; Rodriguez-Bauman, A., Rubin, E. H., Liu, L. F. Ubiquitin/26S proteosome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001, 61, 5926-5932.
7. Liu, L. F., Desai, S. D., Li, T.-K., Mao, Y., Sun, M., Sim, S.-P. Mechanism of Action of Camptothecins. Ann. N. Y. Acad. Sci. 2000, 922, 1-8.
8. Wall, J. G.; Burris, H. A.; Von-Hoff, D. D.; Rodriquez, G.; Kneuper-Hall R.; Shaffer, D.; O'Rourke, T.; Brown, T.; Weiss, G.; Clark, G. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864). Anticancer Drugs 1992, 3, 337-345.
9. Burke, T. G.; Mi, Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J. Med. Chem. 1993, 36, 2580-2582.
10. Burke, T. G.; Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem. 1993, 212, 285-287.
11. Chen, A. Y.; Yu, C., Potmesil, M.; Wall, M. E.; Wani, M. C.; Liu, L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991, 51, 6039-6044.
12. Chu, X., Kato, Y., Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 1997 57, 1934-1938.
13. Kawabata, S.; Oka, M.; Shiozawa, K.; Tsukamoto, K.; Nakatomi, K.; Soda, H.; Fududa; M.; Ikegami, Y.; Sugahara, K.; Yamada, Y.; Kamihira, S.; Doyle, L. A.; Ross, D. D. Kohno, S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 280, 1216-1223.
14. Yang, C. H.; Schneider, E.; Kuo, M. L.; Volk, E. L.; Roccchi; E.; Chen, Y. C.; BCRP/MXR/ABCP expression in topotecan-resistant human breast cancer cells, Biochem. Pharmacol. 2000, 60, 831-837.
15. Scehllens, J. H. M., Melirpaard, M., Scheper, R. J., Scheffer, G. L., Jonker, J. W., Smit, J. W., Beijnen, J. H., and Schinkel, A. H. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Ann. N. Y. Acad. Sci. 2000, 922, 188-194.
16. Kim, J. S.; Gatto B.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. J. Terbenzimidazoles: Influence of 2″-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. J. Med. Chem. 1997, 40, 2818-2824.
17. Ranagarajan, M.; Kim, J. S.; Sim, S.-P.; Liu, A.; Liu, L. F.; LaVoie, E. J. Topoisomerase I inhibition and cytotoxicity of 5-bromo and 5-phenylterbenzimidazoles. Bioorg. Med. Chem. 2000, 11, 2591-2600.
18. Jin, S.; Kim, J. S.; Sim, J. S.; Sim, S.-P.; Liu, A.; Pilch, D. S.; Liu, L. F.; LaVoie, E. J. Heterocyclic bibenzimidazole derivatives as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 719-723.
19. Makhey, D.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. J. Substituted benz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Bioorg. Med. Chem. 2000, 8, 1171-1182.
20. Janin, Y. L.; Croisy, A.; Rious, J.-L.; Bisagni, E. Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J. Med. Chem. 1993, 36, 3686-3692.
21. Makhey, D.; Gatto, B.; Yu, C.; Liu, A.; Liu, L. F.; LaVoie, E. J. Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topoisomerase I and II. Med. Chem. Res. 1995, 5, 1-12.
22. Yamashita, Y.; Fujii, N.; Murakaya C.; Ashizawa, T.; Okabe, M.; Nakano, H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992, 31, 12069-12075.
23. Fujii, N.; Yamashita, Y.; Saitoh; Y.; Nakano H. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J. Biol. Chem. 1993, 268, 13160-13165.
24. Yamashita, Y.; Kawada, S.; Fujii, N.; Nakano, H. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 1991, 30, 5838-5845.
25. Jayaraman, M.; Fox, B. M.; Hollingshead, M.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of new dihydroindeno[1,2-c]indeno[1, 2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model. J. Med. Chem. 2002, 45, 242-249.
26. Cushman, M.; Jayaraman, M.; Vroman, J. A.; Fukunaga, A. K.; Foc, B. M.; Kohlhagen, G.; Strumberg, D.; Pommier, Y. Synthesis of new indeno[1,2-c] isoquinolines; cytotoxic noncamptothecin topoisomerase I inhibitors. J. Med. Chem. 2000, 43, 3688-3698.
27. Ruchelman, A. L.; Singh, S. K.; Liu, A.; Zhou, N.; Liu, L. F.; LaVoie E. J. Cytotoxicity of 5H-Dibenzo[c,h][1,6]naphthyridin-6-ones and 6H-indeno[1,2-c]isoquinolin-5, 11-diones in tumor cells sensitive and resistant to camptothecin analogues. Lett. Drug Des. Disc. 2004, 1, 198-202.
28. Vicker, N.; Burgess, L.; Chuckowree, I. S.; Dodd, R.; Folkes, A. J.; Hardick, D.; Hancox, T. C.; Miller, W.; Milton, J.; Sohal, S.; Wang, S.; Wren, S. P.; Charlton, P. A.; Dangerfield, W.; Liddle, C.; Mistry, P.; Stewart, A. J.; Denny, W. A. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J. Med. Chem. 2002, 45, 721-739.
29. Li, D.; Zhao, B.; Sim, S.-P.; Li, T.-K.; Liu, A.; Liu, L. F.; LaVoie, E. J. 8,9-Methylenedioxybenzo[i]phenanthridines: Topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem. 2003, 11, 3795-3805.
30. Yu, Y.; Singh, S. K.; Liu, A.; Li, T.-K.; Liu, L. F.; LaVoie, E. J. Substituted Dibenzo[c,h]cinnolines: Topoisomerase I-targeting anticancer agents. Bioorg. Med. Chem. 2003, 11, 1475-1491.
31. Ruchelman, A. L.; Singh, S. K.; Wu, X.; Ray, A.; Yang, J.-M.; Li, T.-K.; Liu, A.; Liu, L. F.; LaVoie, E. J. Diaza- and triazachrysenes: Potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg. Med. Chem. Lett. 2002, 12, 3333-3336.
32. Ruchelman, A. L.; Singh, S. K.; Ray, A.; Wu, X.; Yang, J.-M.; Li, T.-K.; Liu, A.; Liu L. F.; LaVoie, E. J. 5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: Novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg. Med. Chem. 2003, 11, 2061-2073.
33. Contreras, J.-M.; Rival, Y. M.; Chayer, S.; Bourguignon, J.-J.; Wermuth, C. G.; Aminopyridazines as acetylcholinesterase inhibitors. J. Med. Chem. 1999, 42, 730-741.
34. Iwanami, S.; Takashima, M.; Hirata, Y.; Hasegawa, O.; Usuda, S. Synthesis and neuroleptic activity of benzamides. cis-N-(1-benzyl-2-methylpyrrolidin-3- yl)-5-chloro-2-methoxy-4-(methyl-amino)benzamide and related compounds. J. Med. Chem. 1981, 24, 1224-1230.
35. Meyer, R. F.; Stratton, C. D.; Hastings, S. G.; Corey, R. M. β-Adrenergic blocking agents. Nitrogen heteroaryl-substituted 2-propanolamines and ethanolamines. J. Med. Chem. 1973, 16, 1113-16.
36. Leclerc, E.; Vrancken, E.; Mangeney, P. Diastereoselective aldolization of α-aminonitriles. diastereoselective synthesis of β-amino alcohols and β,γ-diamino alcohols. J. Org. Chem. 2002, 67, 8928-8937.
37. Pasini, C., Coda, S.; Colo, V.; Ferrini, R.; Glaesser, A. H. Pharmacological effects of some guanidine and guanethidine derivatives. Farmaco Ed. Sci. 1985, 20, 673-685.
38. Saxena, M.; Agarwal, A.; Shiv, K.; Patnaik, G. K.; Saxena, A. K. Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of [β-(aroylamino)ethyl]piperazines and -piperidines and [2-[(aryamino)carbonyl]ethyl]piperazines, -piperidines, - pyrazinopyridoindoles, and -pyrazinoisoquinolines. A new class of potent H1 antagonists. J. Med. Chem. 1990, 33, 2970-2976.
39. Gall-Istok, K.; Sterk, L.; Deak, G. Notes on the Synthesis of 4-Amino-6,7-di-sec-butoxyquinoline, -6,7-Methylenedioxyquinoline and its N-alkylaminoacetyl derivatives. Acta Chim. Hung. 1983, 112, 241-247.
40. Wright, G. C.; Watson, E. J.; Ebetino, F. F.; Lougheed, G.; Stevenson, B. F.; Winterstein, A. Synthesis and hypotensive properties of new 4-aminoquinolines. J. Med. Chem. 1971, 14, 1060-1066.
41. Grigg, R.; Sridharan, V.; Stevenson, P.; Sukirthalingham, S.; Worakun, T. The synthesis of fused ring nitrogen heterocycles via regiospecific intramolecular Heck reactions. Tetrahedron 1990, 46, 4003-4018.
42. Harayama, T.; Akiyama, H.; Kawano, K.; Abe, H.; Takeuchi, Y. Total synthesis of benzo[c]phenanthridine alkaloids, chelerythrine and 12-methoxydihydrochelerythrine, by a palladium-assisted internal biaryl coupling reaction. Synthesis 2001, 444-450.
43. Harayama, T.; Sato, T.; Nakano, Y.; Abe, H.; Takeuchi, Y. Concise synthesis of fagaridine and decarine, phenolic benzo[c]-phenanthridine alkaloids, using the palladium-assisted biaryl coupling reaction. Heterocycles 2003, 59, 293-301.
44. Jacobi, P. A.; Martinelli, M. J.; Polanc, S. Total synthesis of (±)-saxitoxin. J. Am. Chem. Soc. 1984, 106, 5594-5598.
45. Tamura, H.; Kohchi, C.; Yamada, R., Ikeda, T.; Koiwai, O.; Patterson, E.; Keene, J. D.; Okada, K.; Kjeldsen, E.; Nishikawa, K.; Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites, Nucleic Acids Res. 1990, 19, 69-75.
46. Woessner, R. D.; Eng, W. K.; Hofmann, G. A.; Rieman, D. J.; McCabe, F. L.; Hertzberg, R. P.; Mattern, M. R.; Tan, K. B., Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res. 1992, 4, 481-488.
47. Shen, D. W.; Fojo, A.; Chin, J. E.; Roninson, I. B.; Richert, N.; Pastan, I.; Gottesman, M. M. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification, Science 1986, 232, 643-645.
48. Li, T.-K.; Houghton, P. J.; Desai, S. D.; Daroui, P.; Liu, A. A.; Hars, E. S.; Ruchelman, A. L.; LaVoie, E. J.; Liu, L. F. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer agent, Cancer Res. 2003, 63, 8400-8407.
49. Gatto, B.; Sanders, M. M.; Yu C.; Wu, H.-Y.; Makhey, D.; LaVoie, E. J.; Liu, L. F. Identification of topoisomerase I as the cytotoxic target for the protoberberine alkaloid coralyne. Cancer Res. 1986, 56, 2795-2800.
50. Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning, a Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY 1982; pp 149-185.
51. Tewey, K. M.; Rowe, T. C.; Yang, L.; Hallogan, B. C.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984, 226, 466-468.
52. Wang, H.; Mao, Y.; Chen, A.; Zhou, N.; LaVoie, E. J.; Liu, L. F. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 2001, 40, 3316-3323.
53. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
54. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47, 936-942.
55. Denizot, F.; Lang, R. J. Rapid colorimetric assay for cellular growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1988, 89, 271-277.
56. Andoh, T.; Ishii, K.; Suzuki, Y.; Ikegami, Y.; Kusunoki, Y.; Takemoto, Y.; Okada, K. Characterization of a mammalian mutant with a camptothecin- resistant DNA topoisomerase I. Proc. Natl. Acad. Sci., U.S.A. 1987, 84, 5565-5569.
57. Woessner, R. D.; Eng, W. K.; Hofmann, G. A.; Rieman, D. J.; McCabe, F. L.; Hertzberg, R. P.; Mattern, M. R.; Tan, K. B.; Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res. 1992, 4, 481-488.
58. Rubin, E.; Pantazis, P.; Bharti, A.; Toppmeyer, D.; Giovanella, B.; Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem. 1994, 269, 2433-2439.
59. Gervasoni, J. E., Jr.; Fields, S. Z.; Krishna, S.; Baker, M. A.; Rosado, M.; Thuraisamy, K.; Hindenburg, A. A., and Taub, R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991, 51, 4955-4963.
60. Fernandes, D. J.; Danks, M. K.; Beck, W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 1990, 29, 4235-4241.
61. Houghton, P. J.; Cheshire, P. J.; Hallman, J. D.; Lutz, L.; Friedman, H. S.; Danks, M. K.; Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chem.Pharm. 1995, 36, 393-403.